Pneumococcal 15-valent conjugate vaccine Vaxneuvance is now available in Vietnam. (VNVC)
Developed by Merck Sharp & Dohme (MSD) using cutting-edge technology, the vaccine provides protection against 15 dangerous strains of Streptococcus pneumoniae: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.
Vaxneuvance is effective in preventing both invasive and non-invasive pneumococcal diseases, such as Pneumonia, Meningitis, Sepsis, Sinusitis, and Otitis media (middle ear infection).
In addition to providing long-lasting immunity, the vaccine also helps reduce the number of asymptomatic carriers, thereby limiting the spread of infection within the community.
According to the manufacturer, the 15-valent pneumococcal conjugate vaccine has been approved in 65 countries and officially used in more than 40 countries worldwide since 2022.
Dr. Bach Thi Chinh, Medical Director of the VNVC vaccination system, stated that this vaccine is suitable for children from as early as 6 weeks of age and adults. Globally, multiple types of pneumococcal vaccines are in use to protect against severe diseases caused by Streptococcus pneumoniae, including pneumonia, meningitis, and sepsis.
Health experts worldwide emphasise the importance of early and complete vaccination, recommending a combination of pneumococcal vaccines from different generations for broader protection.
With the introduction of the 15-valent pneumococcal vaccine, alongside existing 10-valent, 13-valent, and 23-valent vaccines, VNVC aligns with global trends focused on protecting populations, especially children and the elderly, from fast-spreading, dangerous respiratory infections in today’s highly connected and mobile society.
The World Health Organisation estimates that pneumococcal diseases claim 1.6 million deaths globally each year. Children under 5 and adults over 50, particularly those with chronic illnesses, are the most vulnerable to severe complications and fatal outcomes./.